Forteo musculoskeletal data

The double-blind SHOTZ trial in 58 postmenopausal women with osteoporosis showed that once-daily 20 µg Forteo met the primary endpoint of significantly increasing median mineralizing surface/bone surface, a measure of the proportion of bone surface upon which newly mineralized bone is being deposited, vs. zoledronic acid (5.6% vs. 0.16%, p<0.001). On secondary endpoints, Forteo significantly increased median bone formation rate/bone surface and mineral apposition rate vs. zoledronic acid (p<0.001 and p=0.03, respectively). Data were presented at the American Society for Bone and Mineral Research meeting in San Diego. ...